Overview

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).
Phase:
Phase 3
Details
Lead Sponsor:
Matinas BioPharma Nanotechnologies, Inc.
Collaborator:
University of Minnesota
Treatments:
Amphotericin B
Liposomal amphotericin B